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evaluate whether the value of SUVmax and RI can diagnose as lung 
cancer or the presence of lymph node metastasis.
Results: Eighty-one patients were diagnosed as lung cancer and the 
median SUVmax was 9.2 (range, 0.8 to 24). Ten patients were diag-
nosed as benign nodules and the median SUVmax was 3.1 (range, 1.6 
to 8.9). There was a signiﬁcant difference of SUVmax between lung 
cancer and benign tumor (p<0.001). The correlation between tumor 
size in lung cancer and SUVmax were recognized (r=0.67). If the cut-
off value of SUVmax was 3.5 or greater to depict malignant tumors, the 
sensitivity and speciﬁcity in all pulmonary nodules were 84% and 80%. 
The sensitivity and speciﬁcity in tumors more than 3cm in diameter 
were 98% and 100%. On the other hand, in tumors less than 3cm in 
diameter, the sensitivity and speciﬁcity were 48% and 86%. However, 
if the tumor with either RI of more than 10% or SUVmax of more than 
3.5 is classiﬁed as lung cancer, the sensitivity and speciﬁcity was 83% 
and 86% in tumors less than 3cm in diameter. Four hundred and sixty 
lymph nodes of the hilum and the mediastinum were dissected. Twenty-
one of those were metastatic lymph nodes (4.6%). If the lymph nodes 
with 1cm or greater in minor diameter at the chest CT scan are judged 
with metastasis, the sensitivity, speciﬁcity and accuracy were 50%, 
97% and 33%, respectively. Whereas if the cut-off value of SUVmax 
is 3.5 or greater to depict lymph node metastasis at FDG-PET/CT, the 
sensitivity, speciﬁcity and accuracy were 80%, 99% and 76%, respec-
tively. There were 14 false-positive lymph nodes at the chest CT scan 
and 5 false-positive ones at FDG-PET/CT. 
Conclusion: In the tumors more than 3 cm in diameter, the value of 
SUVmax was a very useful tool for diagnosis of lung cancer. However, 
in the tumors less than 3 cm in diameter, the value of RI in addition to 
SUVmax was useful for diagnosis. FDG-PET/CT was signiﬁcantly bet-
ter than the chest CT scan for diagnosis of lymph node metastasis. 
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Background: This systematic review evaluates the accuracy and utility 
of 18Fluorodeoxyglucose positron emission tomography in the diagno-
sis and staging of both non-small cell and small cell lung cancer.
Methods: Relevant health technology assessments, randomized trials 
and meta-analyses were identiﬁed through a systematic search of the 
literature. The Lung Disease Site Group (LDSG) has used the prac-
tice guideline (PG) development cycle described by Browman GP 
et al (JCO 1998; 16(3):1226-31). A unique aspect of the PG is that it 
incorporates practitioner feedback to evaluate the acceptance of the 
guideline among its practitioners.
Results: One high-quality health technology assessment developed by 
the Institute for Clinical and Evaluative Sciences (ICES) in Ontario 
from 2001 was retrieved and formed the basis for this expanded sys-
tematic review. Twelve additional evidence summary reports, including 
meta-analyses, were reviewed. Thirteen additional prospective studies 
of the diagnostic accuracy of PET and three randomized controlled tri-
als evaluating the utility of PET in staging and diagnosis were retrieved 
in a search of the primary literature published following or beyond 
the scope of the ICES report. PET has high sensitivity, and reasonable 
speciﬁcity for differentiating benign from malignant lesions as small 
as 1 cm in size. PET is superior to CT imaging for mediastinal staging 
in NSCLC. PET has not been studied as extensively in patients with 
SCLC, but the available data shows good accuracy in staging extensive 
versus limited disease. Randomized trials reporting on the utility of 
PET report conﬂicting results in terms of the relative reduction in futile 
thoracotomies. Many studies have evaluated the accuracy of 18FDG-
PET in the diagnosis and staging of lung cancer; however there is 
limited evidence to determine the impact of PET on clinically impor-
tant patient outcomes. 
Practitioner feedback was obtained through a series of mail out ques-
tionnaires to stakeholders that included surgical, medical and radiation 
oncologists as well as nuclear medicine physicians. The itemized ques-
tionnaire elicited feedback regarding the rationale for the guideline, 
completeness of the literature search, and acceptance of the methodol-
ogy and recommendations. The percentage of responses that agreed or 
strongly agreed were 80% (rationale for the guideline), 76% (complete-
ness of literature search), 81% (acceptance of methodology), 56% 
(agree with draft recommendations) and 49% (approve as a guideline).
Conclusion: PET has high sensitivity and reasonable speciﬁcity in 
differentiating benign from malignant processes in lung cancer. PET 
may improve results of early-stage lung cancer by excluding patients 
who have evidence of metastatic disease which is beyond the scope of 
surgical resection and is not evident by standard preoperative staging 
procedures. While the systematic review is regarded as a complete and 
thorough summary of the literature, practitioners disagree on the inter-
pretation of the literature and the clinical utility of PET in the manage-
ment of lung cancer.
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Background: This systematic review evaluates the available evidence 
on the role of Positron Emission Tomography (PET) and Co-registered 
Computed Tomography (CT) simulation in radiation treatment planning 
for lung cancer.
Methods: Relevant studies that incorporated PET or gamma cam-
era coincidence imaging (GCCI) into radiation treatment planning 
were identiﬁed through a systematic search of the published clinical 
literature using major electronic indexes (e.g., MEDLINE, EMBASE, 
COCHRANE). 
Results: Twenty-one studies incorporating PET (n=18) or GCCI (n=3) 
into the radiation treatment planning process for patients with lung can-
cer were identiﬁed from 1996 to 2006. Resolution capabilities of PET 
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or GCCI, co-registration method and accuracy of PET CT co-registra-
tion were not consistently reported. The majority of these studies had 
30 patients or less (15/21) with a range of patient numbers from 11 to 
153. The impact of PET or GCCI on radiation treatment planning was 
also inconsistently reported. PET signiﬁcantly altered the gross target 
volume (GTV) from 20%-100%, and the planning target volume (PTV) 
from 12%-67% in the 9 trials reporting on these outcomes. As well, the 
detection of distant metastases due to PET resulted in the upstaging of 
a substantial number of patients. Limited data were available on the ef-
fect of PET CT in sparing of normal tissues, especially lung (V20) and 
esophagus (V55). The studies varied in the criteria used to deﬁne the 
tumor edge on PET (e.g. thresholding, SUV values). Limited clinico-
pathological correlative data exists for the accuracy of PET CT induced 
changes in the GTV and PTV.
Conclusion: PET CT simulation alters radiation treatment volume 
signiﬁcantly in terms of its changes on GTV and PTV. However, clini-
cal outcomes regarding the accuracy of PET CT changes in radiation 
treatment planning are lacking.
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Objective: to determine the impact of EUS-FNA on management of 
thoracic malignancies. 
Methods: 120 tumour patients referred for invasive diagnostic and 
resection were studied prospectively. Negative and unconclusive EUS-
FNA ﬁndings were assessed by videoassisted mediastinoscopy or open 
lymphadenectomy. 
Results: 120 Patients, aged 64,1 years (range 38-85) underwent 120 
EUS-FNA, 53 videoassisted mediastinoscopic and 48 open lymphad-
enectomies for diagnosis and treatment of 99 lung carcinoma, 6 lung 
metastases, 5 mesothelioma, 2 lymphoma, and 8 other conditions. 
Overall incidence of mediastinal lymph node metastases was 50%, 
detected by EUS-FNA in 41/60 patients. EUS-FNA sensitivity was 
91,7%, 75,0% and 43,8% for bulky disease, enlarged mediastinal nodes 
or normal nodes on CT scan, and 50% resp 96,6% for right- resp left-
sided tumours. EUS-FNA showed T4 in 15/120 and adrenal or hepatic 
metastases in 9/120 cases.
Conclusions: EUS-FNA sensitivity depends on the localisation of the 
primary, and extent of mediastinal disease. Exclusion of mediastinal 
involvement requires mediastinoscopy or open lymphadenectomy. 
For left-sided tumours, EUS-FNA improves mediastinal staging by 
assessing stations 5 & 6 inaccessible to mediastinoscopy. For extended 
mediastinal disease, mediastinoscopy can be avoided or spared for 
restaging after neoadjuvant therapy. Beyond mediastinal nodal staging, 
EUS-FNA may detect T4 and M1 situations. Thus, EUS-FNA is an 
usefull supplement to mediastinoscopy.
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Objective: To compare feasibility and accuracy of video-assisted 
mediastinoscopic lymphadenectomy (VAMLA), a minimally invasive 
technique for systematic mediastinal lymph node dissection, to stan-
dard open lymphadenectomy.
Methods: In a case-control study of 40 patients, VAMLA technique 
was standardized and evaluated against open lymphadenectomy. A 
prospective study investigated 130 patients with resectable lung cancer 
and radiologically normal mediastinum who underwent VAMLA, and 
consecutive lung resection with mediastinal reexploration.
Results: VAMLA harvested signiﬁcantly more lymph nodes than open 
lymphadenectomy (20,7 vs. 14,3, p < 0,0001). Mean duration was 54 
(30-150) min, and the complication rate 4,6%. The incidence of me-
diastinal lymph node metastases was 17,6%.We noted a sensitivity of 
93.8%, a speciﬁcity of 100%, and a false negative rate of 0,9%.
Conclusions: In our experience, VAMLA is a feasible, highly accurate 
method of mediastinal staging. Its radicalitiy can equal open lymph-
adenectomy. However, VAMLA is minimally invasive and therefore 
pretherapeutically available. We suggest the following indications: 
neoadjuvant strategies, trials, involved ﬁeld radiation, VATS lobectomy, 
and left-sided tumours.
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Background: To determine the value of PET-CT in mediastinal lymph 
node staging in NSCLC.
Methods: 44 NSCLC cases who were considered to be operable are 
taken for our study. Fiberoptic bronchoscopy, thorax CT and PET-CT 
were applied in all cases. All cases went through mediastinoscopy. Two 
of the cases underwent an additional mediastinotomy. Of the 10 cases 
who were conﬁrmed to have N2 mediastinoscopycally, 3 were referred 
to surgery after neoadjuvant chemotherapy. Thoracotomy and system-
atic mediastinal sampling was performed to a total of 37 cases.
Results: 
 CT PET-CT Mediastinoscopy
Sensitivity 66.7 80.0 76.9
Spesiﬁtisity 62.1 62.1 100
Accuracy 63.6 68.2 93.2
PPV 47.6 52.2 100
NPV 78.3 85.6 91.2
Conclusions: We have concluded that PET-CT and thorax CT have 
similar diagnostic values in mediastinal lymph node staging and that 
there is no statistical signiﬁcance between the two methods(p>0.05). 
However PET-CT has a high NPV of 85.6%. In our study, false positiv-
ity rate of PET-CT was found to be 47.8%. For this reason, surgical 
